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Biosynthesis of membrane-delve oligosaccharides (MDO), located in the periplasmic space of Escherichia co& was not inhibited by co&in M, 
an inhibitor of bactoprenyl phosphate regeneration. This result suggests that bactoprenol does not serve as a lipid carrier of MDO oligosaccharides 
across the cytoptasmic membrane. 
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I. INTRODUCTION 
Membrane-derived oligosaccharides (MDO) are 
located in the ~riplasmiG space between the outer and 
the cytopiasmic membrane of Esc~e~~e~ia cofi and 
other gram-negative bacteria fl). They are synthesized 
when the external osmolarity is low and serve to 
counterbalance the internal osmotic pressure [2,3]. 
Mutants unable to synthesize MD0 are impaired in 
chemotactic response (motility), show a reduced 
number of flagella, and an enhanced synthesis of the 
OmpC outer membrane porin [4]. MD0 are composed 
of 8-10 glucose units per molecule, which are linked by 
,8 l-2 and ,& 1-6 bonds [S]. The highly branched glucan 
backbone is substituted with sn-1-phosphoglycerol, 
phosphoethanol~ine, and 0-succinyl ester residues 
f61. 
monophosphate. Cleavage of the pyrophosphate bond 
is accomplished by a membrane-bound phosphatase 
[12]. Colicin M interferes with the regeneration of 
bactoprenyl phosphate, and in this way i~ibits murein 
[13] and O-antigen biosynthesis [14]. Inhibition of 
murein synthesis results in lysis of cells which is the 
primary cause of cell killing by this bacterial toxin 
f15,16]. 
In this study we employed colicin M as a tool to study 
the unsettled question of the involvement of bac- 
toprenol in MD0 biosynthesis [17]. We found no in- 
hibition of MD0 biosynthesis by colicin M which 
makes it unlikely that bactoprenol acts as lipid carrier in 
MD0 biosynthesis. 
2. EXPERIMENTAL 
Biosynthesis of MD0 is initiated by transfer of 
glucose from UDP-glucose onto a carrier, and subse- 
quent elongation of the glucan chain through a 
glucosyltransferase system [7]. Octyl-P-D-glucopyra- 
noside can serve as an artificial acceptor in the trans- 
glucosylation reaction suggesting aphysiological carrier 
with a hydroc~bon chain. Css-undecaprenol {bacto- 
prenol) serves as a lipid carrier for the translocation of 
oligosaccharide precursor molecules from the cyto- 
plasm across the cytoplasm&z membrane. This has been 
shown for the biosynthesis of murein (peptidoglyc~) 
[8J, the O-antigen portion of lipopolysaccharide [9& 
teichoic acids IlO], and Kl capsular polysacch~ides 
Ill]. Upon transfer of the oligosaccharides to peri- 
piasmic acceptors, bactoprenyl pyrophosphate is releas- 
ed and reenters the bios~theti~ cycle as bactoprenyl 
2.1. Bacteriai sira& 
The following E. coli K-12 strains were used: MA1008 f&Z43 
pyrc46 thi-1 relA1 spoTI) [is], TAlOO8 (mdoAi pyrC’ MA1008 [4], 
and EH3247 (g1m.S ilv rpsE thi fhr [19], The latter strain was provided 
by Joachim Heltje, Mu-Planck-Inst~tut fiir Entwi~klun~sbioIogie, 
Tiibingen. Strain EH3247 is auxotrophic for GlcN or GlcNAc as it is 
defective in L-gfutamine: D-fructose-&phosphate amino transferase 
{EC 2.6.1.16). We were not able to make this strain defective in MD0 
biosynthesis (mdo) since it already exhibited the two screenable 
phenotypes, loss of motility and slimy colonies on solid media, 
associated with the mdo genotype. 
2.2. Growth co~d~t~o~s 
Bacteria were maintained in TY medium (0.5% tryptone, 0.5% 
yeast extract, 0.25% NaCI) supplemented with 1OOpg GlcNAc/ml or 
IO0 pg uracillml as required. To induce MD0 synthesis cells were 
grown in low osmotic strength medium (peptone medium) containing 
0.5% peptone and 1Opg thiamine/ml supplemented with GlcNAc or 
uraeil as required. Cultures were incubated at 30°C with aeration. 
2.3. Radioiabe~iin~ cells 
Correspondence address: V. Braun, Mikrobiologie II, Auf der At selected times, 1 ml aliquots were taken from actively growing 
Morgensteile 28, Universit~t T~bingen, D-7400 T~bingen, FRG cultures (in peptone medium) and pulse-labeil~ at 30°C for 3 min 
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with 9 kBq (0.9 nmol) D-[U-‘4C]glucose (10.0 GBq/mmol; Amer- 
sham International). After labelling, cells were harvested by cen- 
trifugation and suspended in 40 pl Hz0 and 10 ~1 isobutyric acid. 
Labelled products were separated by descending paper chromato- 
graphy in an isobutyric acid/l M NH40H (5:3) solvent system as 
described elsewhere [13]. Distribution of radioactivity on chroma- 
tograms was determined by liquid scintillation counting 1 cm 
segments of paper cut along the length of the chromatogram, using a 
toluene-based scintillation cocktail. 
2.4. Other procedures 
MD0 used as a chromatographic marker was isolated as previously 
described [4,20] from strain MA1008 labelled with 37 kBq (57 pmol 
D-[2-3H]glucose (Amersham International)/ml culture. Colicin M 
was isolated as described 1211. Colicin-treated cultures were given 
pure colicin M to a final concentration of 0.5 gg/ml. Protein was 
determined by the method of Bradford 1221. 
3. RESULTS AND DISCUSSION 
The column-chromatographic method hitherto used 
to separate MD0 from other components present in the 
50% ethanolic cell extracts was too labor-intensive to 
study the time course of MD0 biosynthesis in the 
presence and absence of a potential inhibitor (colicin 
M). Therefore, a paper chromatographic method with 
great resolving power was employed for MD0 iden- 
tification and quantitation. [3H]glucose-labelled MD0 
purified by column chromatography separated on 
paper between Rf 0.11 and 0.19 with a peak at 0.15. The 
glucose substrate migrated further separating at an Rf 
of 0.49 (fig.lA). Glucose pulse-labelled whole cells of 
strains MA1008 and TA1008 subjected to chro- 
matographic separation yielded 5 major radiolabelled 
peaks (fig.lB). One of these peaks in the MA1008 pro- 
file migrated at the same Rf as the MD0 standard. This 
peak was missing from the chromatographic profile of 
the mdo mutant (strain TA1008). Therefore, MD0 can 
be separated from other labelled cellular components 
by this chromatographic system. The identity of the 
other peaks is not known. It should be possible to ob- 
tain greater resolution of the MD0 peak from the 
neighbouring large peak (Rf 0.23), should this be 
desired, by developing the chromatogram for longer 
periods of time (48-72 h instead of 24 h as was done in 
this study). 
Although biosynthetic precursors of murein biosyn- 
thesis (UDP MurNAc peptides) separate between Rf 
0.1-0.2 with this system [23,24] did not interfere with 
the identification of MDO, probably because their 
amount was much lower than that of MDO. Never- 
theless, we used strain EH3247 for the quantitative 
determination of MD0 as this strain is unable to 
metabolize glucose into GlcNAc which is contained as 
such and as N-acetylmuramic acid derivative in the 
murein glycan chains. Strain EH3247 showed the same 
3 
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Fig.1. Separation pattern of MD0 and glucose (A) and whole cells of strains MA1008 (mdo+) and TAlOOS (mdo) (B) following paper 
chromatography. Samples were radiolabelled and prepared as described in section 2. Developed chromatograms were cut into 1 cm segments tar- 
ting at the origin (Rr 0) and ending at the solvent front (Rf 1.0). Radioactivity of each segment was determined by liquid scintillation counting. 
Symbols used: n , [3H]glucose labelled MDO; 0 n , [‘HI- and [r4C]glucose; l, [‘4C]glucose labelled MAlOOS; 0, [r4C]glucose labelled TAlOOS. 
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radioactivity profile when labelled with [i4C]glucose as 
strain MA1008 (data not shown). 
Strain EH3247 grown in peptone medium lysed ap- 
proximately 20 min after colicin M addition (fig.2). 
Therefore, the strain showed a normal sensitivity to col- 
icin M also in the low osmotic strength medium (i.e., 
slow growth conditions) required for maximal induc- 
tion of MD0 synthesis. 
Quantitation of MD0 synthesized following pulse- 
labelling of strain EH3247 which had been treated with 
colicin M, showed no inhibition of MD0 synthesis 
(table 1). Synthesis continued up to the point of lysis 
and then started to decrease. Residual synthetic activity 
measured during culture lysis was probably due to cells 
which had not yet lysed. 
By comparison synthesis of murein and O-antigen 
were inhibited within the first 5 min of colicin treatment 
(i.e., well before culture lysis) [13,14]. 
If synthesis of MD0 requires the bactoprenyl carrier 
lipid to transfer the polyglucose chains through the 
cytoplasmic membrane into the periplasm, as has been 
predicted 17,251, then a rapid inhibition of MD0 syn- 
thesis would have been expected following colicin M 
treatment as is observed with peptidoglycan and O- 
antigen synthesis. 
The findings presented here rule out the possibility 
that MD0 synthesis occurs via the same lipid carrier 
mechanism used for synthesis of peptidoglycan, O- 
antigen, and Kl capsular polysaccharide. However, 
they do not exclude the use of bactoprenol as a carrier 
if the biochemistry of MD0 release from the carrier dif- 
J-----7 
t -! 
0.6 
t 
0 20 40 
Time (mod 
Fig.2. Effect of colicin M treatment on strain EH247 grown in pep- 
tone medium. One culture was given colicin M at 0 min (m) while the 
second culture remained untreated (0). 
Table 1 
Determination of membrane derived oligosaccharides synthesized by 
strain EH3247 
Time pmol [“‘C]glucose incorporated/ml 
culture 
0 min 
5 min 
10 min 
20 min 
30 min 
Untreated 
22.8 (1.0) 
31.3 (1.4) 
33.8 (1.5) 
38.8 (1.7) 
Colicin M treated 
20.8 (1.0) 
25.6 (1.2) 
29.0 (1.4) 
25.9 (1.2) 
21.3 (1.0) 
Colicin M (0.5rg protein/ml culture) was added to the treated culture 
at 0 min. At times indicated, 1 ml samples of the untreated control 
and colicin M-treated cultures were pulse-labelled with [r4C]glucose 
for 3 min and the amount of radiolabelled glucose incorporated into 
the MD0 fraction was quantitated as described in section 2. Relative 
values are given in parentheses 
fers from the mechanism used for the other oligosac- 
charides. We consider it unlikely that MD0 biosyn- 
thesis would be the exception in using bactoprenol as a 
carrier which is not released as a pyrophosphate 
derivative following transmembrane transfer of the 
MD0 glycan chain. Rather, the finding of an acyl car- 
rier protein as a soluble factor in MD0 biosynthesis [26] 
points to a translocation mechanism across the 
cytoplasmic membrane that differs from the transmem- 
brane transfer of the other oligosaccharides. 
Results presented here are an example of how colicin 
M can be used as a simple tool in determining the in- 
volvement of bactoprenol as a transmembrane carrier. 
Another example where colicin M could be employed as 
a tool is in the study of enterobacterial common antigen 
biosynthesis [27]. In general, bactoprenyl-linked in- 
termediates are difficult to identify due to the low con- 
centration of the carrier although huge amounts of 
precursors (in the order of 6 x lo6 molecules in 20 min) 
are translocated via this lipid across the cytoplasmic 
membrane. 
The paper chromatographic method of isolating and 
quantitating MD0 is both rapid (relative to the more 
laborious column chromatographic procedures 
reported in the literature), reproducible, and permits 
simultaneous eparation of many samples with ease. 
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